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Abstract: von Willebrand Factor (vWF) is a multimeric plasma protein important for platelet plug formation. As part of its   haemostatic 
role, it is released from endothelial cells during vascular stress or injury and is considered an excellent biomarker of endothelial 
  function. Currently, there are no validated kits available to measure vWF in rabbits. We developed a sensitive and reproducible   sandwich 
  enzyme-linked immunosorbent assay (ELISA) for detection of vWF in rabbit plasma using commercially available antibodies and 
reagents. Purified human vWF was used as a calibrator standard with a dynamic range of 1.56–100 ng/mL. The Minimum Required 
Dilution for rabbit plasma was 1:100. When plasma was spiked with 3.76 or 10 ng/mL vWF, recovery was 108 ± 2% and 93 ± 2%, 
respectively. Intra- and inter-assay precision for 8 rabbit plasma samples were 3% and 4%, respectively. The Minimum Detectable 
  Concentration was 254 pg/mL for purified human vWF and 1:10,700 dilution of cholesterol-fed rabbit plasma, and the Reliable   Detection 
Limits were 457 pg/mL and 1:5940. Three freeze-thaw cycles significantly decreased vWF concentrations for purified human vWF and 
2 of 3 plasma samples assayed. This ELISA provides sensitive and reproducible measurements of rabbit plasma vWF, which is an 
important biomarker for cardiovascular research.
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Introduction
Atherosclerosis is a pathological process   underlying 
the  majority  of  clinical  cardiovascular  events1  in 
which chronic inflammatory mechanisms are   culpable 
in  initiation  and  progression.2  Vascular  endothe-
lial cells express adhesion molecules that promote 
the    progression  of  atherosclerosis,3  and  there  is  a 
great deal of interest in discovering biomarkers of 
  endothelial  status  or  inflammation  that  reflect  the 
activity of the various mechanisms at work. These 
biomarkers can assist clinicians and researchers in 
monitoring the progression of atherosclerosis or pre-
dicting  disease  outcomes  in  research  animals  and 
human patients.
One  such  biomarker  is  the  multimeric  plasma 
  protein  von  Willebrand  Factor  (vWF).  In    addition 
to  its  well-established  haemostatic  role,4  vWF  is 
  currently considered the best circulating   biomarker of 
  endothelial function.5 A growing body of   experimental, 
clinical and epidemiological evidence points to high 
plasma vWF levels as indicative of systemic vascular 
dysfunction6 and predictive of acute cardiovascular 
events.7
Our  laboratory  is  interested  in  evaluating  the 
  biological  effects  of  ultrasound,  when  used  with 
  ultrasound  contrast  agents  to  image  the  aorta.  We 
  developed  a  cholesterol-fed  rabbit  model8  for  this 
purpose.  The  vWF  biomarker  would  be  a    useful 
  circulating indicator of endothelial status, but there is 
currently no validated assay kit available to   determine 
vWF levels in rabbit plasma. To facilitate accurate and 
precise measurement of this biomarker in pre-clinical 
studies, we have developed a   sandwich  enzyme-linked 
immunosorbent assay (ELISA)   technique to measure 
rabbit  plasma  vWF  using  commercially  available 
antibodies  and  reagents.  The  assay  was  validated 
by measuring parallelism, spike recovery, intra- and 
inter-assay  precision,  specificity,  sensitivity,  and 
freeze-thaw stability of plasma vWF.
Materials and Methods
Materials
The microplate reader (ELx800) was obtained from 
BioTek  (Winooski,  VT).  Nunc  Immulon  4HBX 
Flat  Bottom  96-well  microplates  and  adhesive 
plate  seals  were  obtained  from  Fisher  Scientific 
(Pittsburgh, PA). Tween-20, Thimerosal, Phosphate 
Buffered Saline (PBS), Na2CO3 and NaHCO3 were 
obtained  from    Sigma-Aldrich  (St.  Louis,  MO). 
The vWF   protein standard (Purified vWF from cit-
rated  human  plasma,  V2650)  was  obtained  from 
US    Biological    (Swampscott,  MA).  Affinity  puri-
fied  goat    anti-human  vWF  (GAVWF-AP),  bioti-
nylated  affinity    purified  goat  anti-human  vWF 
(GAVWF-APBIO),  and  vWF-  deficient  plasma 
(VWF-DP) were obtained from Affinity   Biologicals 
(Ancaster, Ontario, Canada).   Streptavidin-Horseradish 
  Peroxidase (HRP) (016-030-084) and Bovine Serum 
Albumin (BSA) (001-000-162) were obtained from 
  Jackson   ImmunoResearch (West Grove, PA). 3,3′,5,5′- 
Tetramethylbenzidine  (TMB)  substrate  solution 
(52-00-03) and TMB Stop Solution (50-85-05) were 
obtained from KPL (Gaithersburg, MD).
Reagents
Carbonate  Buffer—20  mM  Na2CO3  and  40  mM 
NaHCO3, pH 9.6, stored at 4 °C.
Blocking Buffer—1% w/v BSA in PBS containing 
11.9 mM Phosphates (Na2HPO4, KH2PO4), 137 mM 
NaCl, and 2.7 mM KCl, pH 7.4, stored at −20 °C.
PBST-BSA—0.1% v/v Tween 20, 1% w/v BSA in 
PBS containing 11.9 mM Phosphates, 137 mM NaCl, 
and 2.7 mM KCl, pH 7.4, stored at −20 °C.
Wash  Buffer—0.05%  v/v  Tween  20  in  PBS 
  containing 11.9 mM Phosphates, 137 mM NaCl, and 
2.7 mM KCl, pH 7.4, stored at 4 °C.
All buffers were preserved with 1 mg/L Thimerosal.
Rabbit plasma and protein standard
Four-month-old  male  New  Zealand  White  rabbits 
were acquired from Myrtle’s Rabbitry (Thompson’s 
Station, TN). Animals were housed individually in 
standard caging with stainless steel mesh bottom in 
a 20 °C temperature-controlled room with 12 hour 
light/dark  cycles,  and  fed  either  a  standard  chow 
diet  containing  2%  fat,  0%  cholesterol  and  0.4% 
  magnesium (Harlan Teklad, Indianapolis, IN) or an 
atherogenic diet containing 10% fat, 1% cholesterol, 
and  0.11%  magnesium  (TestDiet,  Richmond,  IN). 
Blood samples were collected in heparinized tubes 
via the lateral saphenous vein while under restraint, 
  centrifuged at 1380 × g for 10 minutes and plasma 
was  aliquotted  and  frozen  at  −70  °C.  The  Institu-
tional   Animal Care and Use Committee at the Uni-
versity of Illinois at Urbana-Champaign approved all 
procedures.von Willebrand Factor eLISA
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The  vWF  protein  standard  was  purified  from 
  citrated human plasma negative for HIV1, HIV2 and 
HBsAg. The protein was supplied at a   concentration 
of  0.2  mg/mL  in  buffer  containing  25  mM 
Na Citrate, 100 mM NaCl, 100 mM glycine, pH 6.8, 
and    determined  by  the  manufacturer  to  be  $95% 
pure  as  judged  by  SDS-PAGE  under  reducing 
  conditions. Upon receipt, the solution was aliquotted 
and stored at −70 °C according to the manufacturer’s 
instructions.
Antibody selection and Optimization
Several  commercially  available  antibodies  were 
  evaluated (Table 1). Affinity purified goat   anti-human 
vWF  and  biotinylated  affinity  purified  goat  anti-
human vWF were selected as capture and sandwich 
antibodies, respectively. Streptavidin-HRP was cho-
sen as the detection reagent. Antibody dilutions were 
  optimized  using  checkerboard  titration  procedures, 
and the   dilutions which returned the strongest signal 
to noise ratio were selected.
procedure
A schematic of the assay procedure can be found in 
Figure 1. Microplate wells were coated with 100 µL 
of  affinity  purified  goat  anti-human  vWF  capture 
antibody diluted 1:5000 in carbonate buffer for a final 
concentration of 1 µg/mL. Plates were covered with 
adhesive sealing film, placed in a plastic bag with 
wet paper towels, and incubated overnight ($16h) at 
4 °C. Reagents were allowed to equilibrate to room 
temperature (RT) overnight.
The  next  day,  plates  were  washed  three  times 
with 300 µL of Wash Buffer per well on an orbital 
shaker with gentle agitation for 5 min. The buffer 
was removed by emptying into a sink and blotting 
on paper towels. Blocking Buffer (300 µL) was then 
added to each well and plates were sealed and blocked 
for 2 hours at RT with agitation.
During this time, rabbit plasma samples and the 
vWF standard were prepared for addition to the plate. 
A standard curve was generated by serially   diluting 
the  0.2  mg/mL  vWF  stock  in  Blocking    Buffer. 
Table 1. vWF antibody selection.
company catalog 
number
Host Immunogen Type Application Works in 
rabbit?
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some lots

















SAcWF-Ig Sheep canine vWF Polyclonal 
Igg
capture Yes

































notes: Several antibodies were evaluated for effectiveness in detecting rabbit vWF. Some antibodies detected neither rabbit plasma vWF nor purified 
human vWF (the putative antigen) in this experimental setup. When the Abcam goat anti-human vWF antibody was used in the sandwich configuration,   
a donkey anti-goat Igg antibody (novus nB7357) was used as the detection reagent. When the sandwich antibody was biotinylated, Streptavidin-hrP 
was used as the detection reagent.Smith et al
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Working dilutions of 100, 50, 25, 12.5, 6.25, 3.13 and 
1.56 ng/mL were used in the assay. These   dilutions 
span the concentration range of diluted plasma sam-
ples. Rabbit plasma was diluted 1:100 in Blocking 
Buffer.  Following  the  blocking  step,  plates  were 
washed three times with Wash Buffer as described 
above and 100 µL of each standard and sample were 
added to the plate in duplicate. Blocking Buffer alone 
was used as a blank. Plates were incubated for 2 hours 
at RT with agitation.
Plates were then emptied into a sink and washed 
three  times  with Wash  Buffer  as  described  above. 
Biotinylated  affinity  purified  goat  anti-human 
vWF was diluted 1:40,000 in PBST-BSA to a final 
  concentration of 25 ng/mL and 100 µL were added to 
each well. Plates were sealed and incubated for 1 hour 
at  RT  with  agitation. After  emptying  the  previous 
solution and washing, Streptavidin-HRP was diluted 
1:100,000 in PBST-BSA to a final concentration of 
5 ng/mL and 100 µL were added to each well. Plates 
were sealed, protected from light and incubated for 
1 hour at RT with agitation.
After removing the Streptavidin-HRP solution and 
washing, 100 µL of the TMB substrate were added to 
each well. The reaction was stopped after 5 min by 
addition of 100 µL TMB Stop Solution per well and 
allowed to equilibrate for 5 min. The underside of the 
microplate was wiped with 70% ethanol and the plate 
Step 1: Coat plate with




























































































    Microplate well
Figure 1. Schematic illustrating the sandwich eLISA procedure.von Willebrand Factor eLISA
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was read immediately at 450 nm with wavelength 
correction at 550 nm using a microplate reader.
A linear standard curve was generated using the 
duplicate blanked readings from the serially diluted 
protein standard. Samples were interpolated into the 
standard curve to obtain concentration values. The 
dynamic range of the standard curve utilized in this 
assay is 1.56–100 ng/mL. The TMB incubation time 
was optimized to provide a reading of 1.5 absorbance 
units for the most concentrated standard.
Specificity
To test for non-specific signal, control wells   containing 
either  Blocking  Buffer  or  human  plasma  rendered 
immunodeficient for vWF were incorporated into each 
assay. In other experiments, wells were also included 
where  rabbit  plasma  samples  were  assayed  in  the 
absence of either the capture or sandwich antibody.
Minimum Required Dilution
Minimum  Required  Dilution  (MRD)  is  identified 
when establishing parallelism and is defined as the 
minimum sample dilution providing optimal   accuracy 
and precision.9 Plasma from six cholesterol-fed   rabbits 
was pooled, subjected to dilutions between 1:6.25 and 
1:200 and assayed in quadruplicate.   Parallelism was 
defined as dilution-corrected analyte   concentrations 
varying  #20%  between  dilutions.10  The  minimum 
dilution  achieving  parallelism  was  chosen  as  the 
MRD.
spike Recovery
Cholesterol-fed  rabbit  plasma  was  spiked  with 
  purified vWF at concentrations of 3.76 ng/mL (Low 
Spike) and 10 ng/mL (High Spike). Plasma, spikes, 
and spiked plasma were each assayed in   quadruplicate 
on  the  same  plate.  Recovery  was    calculated  using 
vWF  concentration  values  with  the  equation: 
(([Sample+Spike]−[Sample])/[Spike])*100.   Brackets 
denote  a  concentration  value  in  ng/mL.  Standard 
deviation (SD) was obtained from the two sets of 
duplicate values. The measured concentration of the 
spiked sample should be within 20% of the expected 
value.9
precision
Eight  plasma  samples  from  cholesterol-fed  rabbits 
were  selected.  Each  sample  was  diluted  1:100  in 
Blocking  Buffer  and  10  replicates  were  plated  to 
determine intra-assay precision. This experiment was 
repeated over three different days with   parallel   aliquots 
to  evaluate  inter-assay  precision.  We    previously 
assayed parallel aliquots of the samples for plasma 
total cholesterol (Table 4) using an enzymatic colori-
metric kit (Wako Chemicals, Richmond, VA).
sensitivity
Eighteen  serial  dilutions  of  purified  vWF  were 
  prepared beginning with 400 ng/mL and assayed in 
quadruplicate, along with 24 replicates of the zero 
concentration  buffer  blank.  A  similar  procedure 
was  followed  for  rabbit  plasma.  Plasma  from  six 
  cholesterol-fed rabbits was pooled and subjected to 
serial dilutions from 1:6.25 to 1:102,000.
Freeze-Thaw stability of samples
Freeze-thaw  stability  was  determined  over  three 
freeze-thaw  cycles.  Three  rabbit  plasma  samples 
were selected. Separate aliquots of each sample were 
thawed between 1–3 times by removal from the −70 °C 
freezer and thawing on ice for #2 hours. They were 
then returned to the freezer and stored as before. All 
samples and aliquots were diluted 1:100 and assayed 
on the same plate, with 6 replicates per aliquot, along 
with 6 replicates of purified vWF at 100 ng/mL. Any 
significant  changes  in  assay  response  were  deter-
mined using repeated-measures ANOVA followed by 
Bonferroni adjustment for multiple comparisons.
calculations and Analysis
Data  are  presented  as  means  ±  SD. All  standards 
and samples were run in duplicate unless otherwise 
noted.  Data  were  analyzed  using  SigmaPlot  10.0 
and PASW Statistics 18.0 for Windows, and mean 
  differences were considered statistically significant at 
the P , 0.05 level.
Results and Discussion
ELISA is the most widely used method of   screening 
mammalian plasma for vWF, replacing the   Laurell 
techniques  previously  used.11  Several  publica-
tions have utilized the vWF marker specifically in 
  rabbits. De Meyer and coworkers12 utilized immu-
nohistochemistry to qualitatively observe deposition 
of vWF in the vascular intima. The group reported 
lack of an available measurement method for rabbit Smith et al
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plasma vWF. An earlier publication by Benson et al13 
reported adaptation of an ELISA for measurement of 
plasma vWF in rabbit and other species, but neither 
demonstrated quantitative data for rabbits nor used 
commercially available antibodies. Benson et al did, 
however, highlight the important ability to construct a 
vWF assay without species-specific antibodies.
Two subsequent publications attempted to   quantify 
rabbit plasma vWF by sandwich ELISA. The first14 
merely  reported  optical  density  values  obtained  in 
each assay, which is not useful to other   researchers. 
It is commonly known that optical density values vary 
between assays due to many factors such as   activity 
of  the  peroxidase  conjugate,  binding  of  antigen  to 
antibodies, or temperature conditions, and thus it is 
critical to include a standard curve in each assay using 
purified analyte. A second publication15 quantified rab-
bit plasma vWF, and found that the marker   correlated 
well  with  development  of  atherosclerosis,  but  pro-
vided  inadequate  detail  about  the  ELISA  method 
utilized. Neither of these two assays was validated. 
Furthermore, cholesterol feeding elevates blood cho-
lesterol to extremely high levels, a potential source of 
interference in an immunoassay. We   developed and 
validated an ELISA to improve upon previous work.
An assay that appears precise but measures the 
wrong analyte would not be valid. We confirmed the 
specificity of the antibodies used by including   positive 
(the purified vWF standard) and negative (vWF defi-
cient  plasma)  controls.  Antibodies    demonstrated 
strong affinity for purified vWF. Omission of either 
the capture or sandwich antibody did not result in any 
signal above that of the buffer blank. Additionally, 
when vWF-deficient human plasma was assayed, no 
signal above blank was seen (data not shown).
Parallelism  and  spike  recovery  are  important 
  considerations when working with complex   matrices 
such as blood plasma.18 Lipids and other   interfering 
substances in plasma can lead to assay variation, but 
diluting the sample matrix helps minimize these effects. 
Assaying an undiluted sample can also   underestimate 
the  amount  of  analyte  present,    presumably  due  to 
saturation  of  the  antibodies.  We  observed  this  in 
our results. When rabbit plasma was serially diluted 
beginning with a 1:6.25 dilution, the MRD was 1:100 
(Table 2). Dilution-corrected   concentrations increased 
from 429 ng/mL in the 1:6.25 dilution to 2440 ng/mL 
at the 1:100 MRD. Spike recovery analysis is also useful 
in assessing accuracy and sample matrix   interference. 
  Theoretically, an identical assay response should be 
seen for a given amount of vWF, whether it is present 
in plasma or purified and diluted in a buffer. In order to 
  demonstrate this, plasma is spiked with vWF and the 
concentration determined. The observed (uncorrected 
for dilution) vWF   concentration of the cholesterol-
fed rabbit plasma was 16.2 ng/mL. When plasma was 
spiked with 3.76 ng/mL vWF, the   measured concen-
tration was 20.3 ng/mL, which   represents a recovery 
of 108 ± 2%. When plasma was spiked with 10 ng/mL 
vWF, the measured concentration was 25.5 ng/mL, 
which represents a recovery of 93 ± 2% (Table 3).
Measurement  reproducibility,  or  precision,  is  a 
  crucial aspect of any bioanalytical method.   Intra-assay 
precision is the variability between   replicates of the 
same sample in an assay, and inter-assay precision 
is the variability over multiple days. CV was used 
as  a  measure  of  precision  and  defined  as  (Mean/
Standard  Deviation)*100.16  Recommended  CV 






cV, % % concentration 
of previous 
dilution
6.25 429 2 –
12.5 794 6 185
25 1360 2 171
50 2080 7 154
100 2440 5 117
200 2420 12 99
notes:  Plasma  from  six  cholesterol-fed  rabbits  was  pooled,  diluted 
starting at 1:6.25 and assayed in quadruplicate. The MRD is the first 
dilution to fall within 20% of the previous dilution’s concentration.





Mean ± sD, %
rabbit Plasma 16.2
Low Spike 3.76
Low Spike + Plasma 20.3 108 ± 2
high Spike 10.0
high Spike + Plasma 25.5   93 ± 2
notes:  Rabbit  plasma  was  spiked  with  purified  human  vWF  at 
concentrations of 3.76 ng/mL (Low Spike) and 10 ng/mL (high Spike). 
Plasma, spikes, and spiked plasma were each assayed in quadruplicate 
on  the  same  plate.  A  concentration  within  20%  of  expected  was 
considered acceptable recovery.von Willebrand Factor eLISA
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Table 4. Precision.

















rabbit 1 1100 1730 42 3 2
rabbit 2 868 2430 66 4 3
rabbit 3 897 3240 153 3 5
rabbit 4 950 2290 153 3 7
rabbit 5 906 3280 127 2 4
rabbit 6 691 2600 68 2 3
rabbit 7 1000 2200 130 2 6
rabbit 8 1070 2720 77 4 3
Average 935 2560 102 3 4
notes:  eight  plasma  samples  from  cholesterol-fed  rabbits  were 
selected. each sample was diluted 1:100 in Blocking Buffer and run with 
10 replicates. The experiment was repeated over three different days 
with parallel aliquots to determine inter-assay precision. Intra-assay cV 
and vWF values represent means of the three experiments.
for   immunoassays is #20% (17, 18). Our   average 
  intra-assay  CV  of  3%  is  well  within  this  guide-
line (Table 4). Measurement of the same 8 plasma 
  samples on three different days yielded an inter-assay 
CV = 4% (Table 4). Thus, this assay provides precise 
and reproducible measurements of plasma vWF.
These data also illustrate the excellent selectivity 
of the assay. Selectivity is commonly defined as the 
ability of the antibodies to bind consistent amounts 
of protein in the presence of other interfering agents, 
such  as  lipids  and  plasma  matrix  components. 
The antibodies bind both purified human vWF and 
rabbit vWF in plasma with equally high precision, 
despite potential interference from an average total 
  cholesterol level of 935 mg/dL in the 8 rabbit plasma 
samples used (Table 4). It is recommended to estab-
lish and confirm selectivity of an immunoassay in dis-
ease states,18 however this is rarely done. Our assay is 
effective in atherosclerotic, hyperlipidemic animals.
Statistical measures used to evaluate assay sensitiv-
ity include Minimum Detectable   Concentration (MDC) 
and Reliable Detection Limit (RDL). The MDC is the 
concentration at which there is a high probability of a 
response significantly lower than the blank. The RDL, 
conversely, is the lowest concentration of analyte that 
produces  a  response    significantly  greater  than  the 
blank.19 A 4-parameter logistic regression curve was 
fit to the data20 and 95% Confidence Intervals (CIs) 
of the curve were calculated.   Graphically, the MDC 
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Figure 2. Sensitivity. A) 18 serial dilutions of purified vWF were   prepared 
beginning  with  400  ng/mL  and  assayed  in  quadruplicate,  along  with 
24 replicates of the zero concentration buffer blank. B) rabbit plasma 
was  subjected  to  serial  dilutions  beginning  at  1:6.25  and  assayed 
in    quadruplicate.  4-parameter  logistic  regression  curves  with  95% 
  Confidence Intervals were fit to the data. Bars are SD. 
Abbreviations: MDc, Minimum Detectable concentration. rDL, reli-
able Detection Limit.
with an asymptote drawn horizontally from the upper 
95% CI of the 4-PL curve at zero concentration. The 
RDL lies at the intersection of the lower 95% CI of 
the 4-PL curve of the standards data with an asymp-
tote drawn horizontally from the upper 95% CI of 
the 4-PL curve at zero concentration. The MDC and 
RDL were 254 and 457 pg/mL for the vWF standard 
and 1:10,700 and 1:5940 for rabbit plasma (Fig. 2). 
This assay is versatile and could easily be adapted 
to assay protein levels in the single-digit picogram 
range  simply  by    increasing  the  Streptavidin-HRP 
concentration.Smith et al
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The sensitivity of an ELISA is largely dependent on 
the antibodies used. High sensitivity requires two well-
paired antibodies. Theoretical support for the use of 
these antibodies in screening rabbit plasma is provided 
by  previous  work  which  demonstrated  87%  homol-
ogy between human and rabbit vWF cDNA sequences, 
including 100% homology in the region corresponding 
to the first 116 amino acids of the N-terminal domain 
of the mature vWF subunit.21 The aforementioned mul-
tispecies ELISA13 provided additional evidence of the 
high degree of homology of vWF molecules from many 
vertebrate species, and the resultant cross-reactivity of 
many anti-vWF antibodies.
Protein  stability  over  multiple  thaw  cycles  is  an 
important  practical  consideration  when  handling 
  biological specimens. Freeze-thaw cycles commonly 
reduce protein stability, and our results suggest that 
vWF  is  degraded  after  multiple  freeze-thaw  cycles. 
Decreases reached statistical significance for most sam-
ples, with mean absorbances 7%–17% lower after three 
freeze-thaws (Table 5). Absorbance readings for Sam-
ples 2 and 3 were significantly different between 1 and 
3 freeze-thaw cycles (P , 0.001). Absorbance readings 
for the vWF standard at 100 ng/mL were significantly 
decreased after 3 freeze-thaw cycles compared with 1 
(P , 0.01) and 2 (P , 0.05) freeze-thaw cycles. Sam-
ple 2 showed a 7% decrease in mean absorbance after 3 
freeze-thaws, Sample 3 a 17% decrease, and the 100 ng/
mL vWF standard a 9% decrease. While the decrease 
for Sample 1 was not statistically significant, the mean 
absorbance was 15% lower after 3 freeze-thaw cycles. 
It is advisable to aliquot all specimens prior to freezing 
for the first time to avoid these complications.
In  conclusion,  we  have  described  an  accurate, 
  precise and sensitive method to analyze rabbit plasma 
for vWF that has been formally validated in   accordance 
with current recommendations. To our knowledge, this 
is the only currently available   validated ELISA for rab-
bit vWF and may prove useful in the ongoing search 
for suitable biomarkers of atherogenesis and endothe-
lial damage.
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